FDA Grants Clearance for Phase 3 Study of Lisaftoclax in Previously Treated CLL/SLL
The FDA has granted clearance for a global, registrational, phase 3 study examining lisaftoclax in combination with a BTK inhibitor in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received prior treatment with a BTK inhibitor.
Ascentage Pharma Yifan Zhai Chronic Lymphocytic Leukemia Apg 2575 Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
Source: onclive.com